Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.38 |
| ▸ | ACACA | Q13085 | 4/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 8/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | KDM6B | O15054 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923328 | 0.90 | ACACB (0.43) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL29923261 | 0.90 | ACACB (0.43) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL29923308 | 0.89 | KDM4C (0.40) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL29923427 | 0.89 | KDM4C (0.40) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL29923093 | 0.88 | CKS1B (0.37) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL29923202 | 0.87 | CKS1B (0.39) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL29923318 | 0.86 | ACACB (0.42) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL29923565 | 0.86 | ACACB (0.42) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL29923405 | 0.86 | CKS1B (0.40) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL27230955 | 0.85 | KDM4C (0.41) | KDM4CKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150330-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2022217232-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150330-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | TAAR1, HTR1A, HTR1F | ACACB 4777/4885ACACA 4121/4885CKS1B 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.